Megan M. Chang

Megan M. Chang

Auto-generated profile, based on publicly available information

Megan M. Chang

Department of Bioengineering, University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
KKKathryn A. Kundrod
Kathryn A. Kundrod
MBMaria Barra
Maria Barra
AWAlexis Wilkinson
Alexis Wilkinson
CSChelsey A. Smith
Chelsey A. Smith
MNMary E. Natoli
Mary E. Natoli
RRRebecca Richards-Kortum
Rebecca Richards-Kortum
High-risk human papillomavirus (HPV) DNA testing is widely acknowledged as the most sensitive cervical cancer screening method but has limited availability in resource-limited settings, where the burden of cervical cancer is highest. Recently, HPV DNA tests have been developed for use in resource-limited settings, but they remain too costly for widespread use and require instruments that are often limited to centralized laboratories. To help meet the global need for low-cost cervical cancer screening, we developed a prototype, sample-to-answer, point-of-care test for HPV16 and HPV18 DNA. Our test relies on isothermal DNA amplification and lateral flow detection, two technologies that reduce the need for complex instrumentation. We integrated all test components into a low-cost, manufacturable platform, and performance of the integrated test was evaluated with synthetic samples, provider-collected clinical samples in a high-resource setting in the United States, and self-collected clinical samples in a low-resource setting in Mozambique. We demonstrated a clinically relevant limit of detection of 1000 HPV16 or HPV18 DNA copies per test. The test requires six user steps, yields results in 45 min, and can be performed using a benchtop instrument and minicentrifuge by minimally trained personnel. The projected per-test cost is <$5, and the projected instrumentation cost is <$1000. These results show the feasibility of a sample-to-answer, point-of-care HPV DNA test. With the inclusion of other HPV types, this test has the potential to fill a critical gap for decentralized and globally accessible cervical cancer screening.

25 February 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KKKathryn A. Kundrod
Kathryn A. Kundrod
MNMary E. Natoli
Mary E. Natoli
MCMegan M. Chang
Megan M. Chang
CSChelsey A. Smith
Chelsey A. Smith
SPSai Paul
Sai Paul
RRRebecca Richards-Kortum
Rebecca Richards-Kortum
The global COVID-19 pandemic has highlighted the need for rapid, accurate and accessible nucleic acid tests to enable timely identification of infected individuals. We optimized a sample-to-answer nucleic acid test for SARS-CoV-2 that provides results in <1 hour using inexpensive and readily available reagents. The test workflow includes a simple lysis and viral inactivation protocol followed by direct isothermal amplification of viral RNA using RT-LAMP. The assay was validated using two different instruments, a portable isothermal fluorimeter and a standard thermocycler. Results of the RT-LAMP assay were compared to traditional RT-qPCR for nasopharyngeal swabs, nasal swabs, and saliva collected from a cohort of patients hospitalized due to COVID-19. For all three sample types, positive agreement with RT-LAMP performed using the isothermal fluorimeter was 100% for samples with Ct <30 and 69–91% for samples with Ct <40. Following validation, the test was successfully scaled to test the saliva of up to 400 asymptomatic individuals per day as part of the campus surveillance program at Rice University. Successful development, validation, and scaling of this sample-to-answer, extraction-free real-time RT-LAMP test for SARS-CoV-2 adds a highly adaptable tool to efforts to control the COVID-19 pandemic, and can inform test development strategies for future infectious disease threats.

22 December 2022 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
CSChelsey A. Smith
Chelsey A. Smith
MCMegan M. Chang
Megan M. Chang
KKKathryn A. Kundrod
Kathryn A. Kundrod
ENEmilie N. Novak
Emilie N. Novak
SPSonia G. Parra
Sonia G. Parra
RRRebecca Richards-Kortum
Rebecca Richards-Kortum
A low-cost, user friendly 2DPN for cervical cancer screening was developed and validated for detection of high-risk HPV DNA in clinical samples.

25 July 2024 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
MCMegan M. Chang
Megan M. Chang
MNMary E. Natoli
Mary E. Natoli
AWAlexis F. Wilkinson
Alexis F. Wilkinson
VTVenée N. Tubman
Venée N. Tubman
GAGladstone E. Airewele
Gladstone E. Airewele
RRRebecca Richards-Kortum
Rebecca Richards-Kortum
Isothermal nucleic acid amplification tests have the potential to improve disease diagnosis at the point of care, but it remains challenging to develop multiplexed tests that can detect ≥3 targets or to detect point mutations that may cause disease. These capabilities are critical to enabling informed clinical decision-making for many applications, such as sickle cell disease (SCD). To address this, we describe the development of a multiplexed allele-specific recombinase polymerase amplification (RPA) assay with lateral flow readout. We first characterize the specificity of RPA using primer design strategies employed in PCR to achieve point mutation detection, and demonstrate the utility of these strategies in achieving selective isothermal amplification and detection of genomic DNA encoding for the healthy βA globin allele, or genomic DNA containing point mutations encoding for pathologic βS and βC globin alleles, which are responsible for most sickle cell disorders. We then optimize reaction conditions to achieve multiplexed amplification and identification of the three alleles in a single reaction. Finally, we perform a small pilot study with 20 extracted genomic DNA samples from SCD patients and healthy volunteers – of the 13 samples with valid results, the assay demonstrated 100% sensitivity and 100% specificity for detecting pathologic alleles, and an overall accuracy of 92.3% for genotype prediction. This multiplexed assay is rapid, minimally instrumented, and when combined with point-of-care sample preparation, could enable DNA-based diagnosis of SCD in low-resource settings. The strategies reported here could be applied to other challenges, such as detection of mutations that confer drug resistance.

16 June 2022 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
ENEmilie I. Newsham
Emilie I. Newsham
EPElizabeth A. Phillips
Elizabeth A. Phillips
HMHui Ma
Hui Ma
MCMegan M. Chang
Megan M. Chang
SWSteven T. Wereley
Steven T. Wereley
JLJacqueline Linnes
Jacqueline Linnes
Wax valves were modeled and optimized for use in multi-step paper-fluidic devices. Micro-particle image velocimetry quantified microscale flow in nitrocellulose.

17 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CBCara Brainerd
Cara Brainerd
MSMaya Abigail Singh
Maya Abigail Singh
JTJohn Tatka
John Tatka
CCCosette Craig
Cosette Craig
SGShane Gilligan-Steinberg
Shane Gilligan-Steinberg
AOAyokunle Olanrewaju
Ayokunle Olanrewaju
Maintaining adequate levels of antiretroviral (ARV) medications is crucial for the efficacy of HIV treatment and prevention regimens. Monitoring ARV levels can predict or prevent adverse health outcomes like treatment failure or drug resistance. However, conventional ARV measurement using liquid chromatography-tandem mass spectrometry (LC-MS/MS) is slow, expensive, and centralized delaying clinical and behavioral interventions. We previously developed a rapid enzymatic assay for measuring nucleotide reverse transcriptase inhibitors (NRTIs) — the backbone of HIV treatment and prevention regimens — based on the drugs' termination of DNA synthesis by HIV reverse transcriptase (RT) enzyme. Here we expand our work to include non-nucleoside reverse transcriptase inhibitors (NNRTIs) — an ARV class used in established and emerging HIV treatment and prevention regimens. We demonstrate that the REverse Transcriptase ACTivity (REACT) assay can detect NNRTIs including medications used in oral and long-acting/extended-release HIV treatment and prevention. We demonstrate that REACT can measure NNRTIs spiked in either buffer or diluted plasma, and that fluorescence can be measured on both a traditional plate reader and an inexpensive portable reader that can be deployed in point-of-care (POC) settings. REACT measured clinically relevant concentrations of five NNRTI spiked in aqueous buffer. REACT measurements showed excellent agreement between the plate reader and the portable reader, with a high correlation in both aqueous buffer (Pearson's r=0.9807, P < 0.0001) and diluted plasma (Pearson's r = 0.9681, P < 0.0001). REACT has the potential to provide rapid measurement of NNRTIs in POC settings and may help to improve HIV treatment and prevention outcomes.